Hims & Hers Health Crashes After Novo Nukes GLP-1 Partnership Over “Illegal Mass Compounding” Scheme
Shares of Hims & Hers Health crashed in premarket trading after Novo Nordisk terminated its GLP-1 partnership with the telehealth firm, citing violations of federal law related to mass sales of compounded drugs disguised as “personalized” treatments, along with deceptive marketing practices that allegedly jeopardized patient safety.
Novo Nordisk terminates collaboration with HIMS, stock plunges
— zerohedge (@zerohedge) June 23, 2025
Following the FDA’s resolution of the national Wegovy shortage in April, Novo partnered with select telehealth companies, including Hims & Hers, to transition patients from unregulated, compounded versions to the approved version of Wegovy. However, Novo alleges that Hims & Hers failed to comply with legal and safety standards…
Here’s more from Novo:
In late April, the FDA resolved the Wegovy shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy through NovoCare Pharmacy, Novo Nordisk began collaborating with telehealth companies. Over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of “personalization” and are disseminating deceptive marketing that put patient safety at risk.
Novo Nordisk is deeply concerned and is continuing to take proactive measures to keep US patients safe from knock-off drugs made with foreign illicit active pharmaceutical ingredients. Based on Novo Nordisk’s investigation, the “semaglutide” active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China.
NOVO terminates Hims & Hers collaboration citing HIMS “illegal mass compounding and deceptive marketing.”
Resounding endorsement for HIMS, should be down 50% shortly after their primary source of upside accused them of being criminals. https://t.co/aCyXPuYtTD
— zerohedge (@zerohedge) June 23, 2025
Dave Moore, Executive Vice President, US Operations of Novo Nordisk, stated:
“Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy.
“We will work with telehealth companies to provide direct access to Wegovy® that share our commitment to patient safety – and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action.”
In markets, shares of Hims & Hers Health plunged as much as 20% in premarket trading.
This comes after the stock closed near a 52-week high of around $64 on Friday. Short interest has surged to 34.8% of the float—equivalent to roughly 61 million shares—highlighting elevated bearish positioning.
The partnership is still prominently featured on Hims & Hers Health’s website.
Hims & Hers’ entire business model is now under scrutiny, after its largest partner—Novo Nordisk—effectively exposed it as built on grey areas. What was marketed as “personalized care” is looking like a mass-scale compounding scheme…
Tyler Durden Mon, 06/23/2025 – 08:50
Source: https://freedombunker.com/2025/06/23/hims-hers-health-crashes-after-novo-nukes-glp-1-partnership-over-illegal-mass-compounding-scheme/
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
